Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
The company is reporting complete results from Cohort 1 of the trial, which includes 16 patients (12 who received soquelitinib 100 mg oral twice per day and four who received placebo), with follow-up at 28 days and 58 days.Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
Corvus Pharmaceuticals, Inc. (纳斯达克:CRVS) 发布了评估soquelitinib治疗中重度特应性皮炎患者的1期临床试验的中期数据。
The trial will enroll 64 patients with moderate to severe atopic dermatitis who previously failed one prior topical or systemic therapy.
该试验将招募64名之前未能接受一种局部或系统治疗的中重度特应性皮炎患者。
These doses were selected based on the company's prior experience evaluating soquelitinib in T-cell lymphoma patients.
这些剂量是基于公司之前在t细胞淋巴瘤患者中评估soquelitinib的经验而选择的。
The company is reporting complete results from Cohort 1 of the trial, which includes 16 patients (12 who received soquelitinib 100 mg oral twice per day and four who received placebo), with follow-up at 28 days and 58 days.
该公司正在报告试验第一组的完整结果，第一组包括16名患者（12名接受soquelitinib 100 mg口服，每天两次，4名接受安慰剂），随访时间为28天和58天。
The mean baseline EASI and IGA scores for soquelitinib patients were 20.4 and 3.0, respectively, compared to 18.5 and 3.3 for placebo patients.
soquelitinib患者的平均基线EASI和IGA分数分别为20.4和3.0，而安慰剂患者的分数为18.5和3.3。
EASI scores at 28-day and 58-day follow-up demonstrate a favorable effect of soquelitinib treatment compared to placebo.
在28天和58天的随访中，EASI分数显示出soquelitinib治疗与安慰剂相比具有良好的效果。
The soquelitinib mean EASI score reduction was 55.9% at 28 days (n=12) compared to mean EASI reduction of 27.0% in placebo. At day 58, continued improvement in the soquelitinib group was seen with mean EASI reduction of 69.1% (n=10) compared to mean EASI reduction of 19.1% for the placebo group.
在28天时，soquelitinib的平均EASI分数减少了55.9%（n=12），而安慰剂的平均EASI减少了27.0%。在58天时，soquelitinib组的持续改善表现为平均EASI减少了69.1%（n=10），而安慰剂组的平均EASI减少了19.1%。
- At day 28, in the soquelitinib group, nine of 12 patients achieved EASI 50; three of 12 achieved EASI 75 and one of 12 achieved EASI 90. Three of the 12 patients achieved IGA 0 or 1. In the placebo group, two of four patients achieved EASI 50 and none achieved EASI 75, EASI 90, or IGA 0 or 1.
- At day 58, in the soquelitinib group, nine of 10 patients achieved EASI 50, four of 10 achieved EASI 75 and one of 10 achieved EASI 90. Three of 10 patients achieved IGA 0 or 1. In the placebo group, one in four patients achieved EASI 50, and no patients achieved EASI 75, EASI 90, or IGA 0 or 1.
- 在第28天，soquelitinib组中，12名患者中有9名达到了EASI 50；3名达到了EASI 75，其中1名达到了EASI 90。12名患者中有3名达到了IGA 0或1。在安慰剂组中，4名患者中有2名达到了EASI 50，且没有患者达到EASI 75、EASI 90或IGA 0或1。
- 在第58天，索奎利替尼组中，10名患者中有9名达到了EASI 50，4名达到了EASI 75，1名达到了EASI 90。10名患者中有3名达到了IGA 0或1。在安慰剂组中，四分之一的患者达到了EASI 50，没有患者达到了EASI 75、EASI 90或IGA 0或1。
No significant safety issues were observed. All the patients completed 28 days of dosing. One patient reported Grade 1 nausea that did not interfere with the subject receiving the full treatment course, and one patient developed COVID-19 on day 28 of treatment; that patient had an uneventful recovery.
没有观察到显著的安全性问题。所有患者完成了28天的给药。一名患者报告了1级恶心，但没有影响患者接受完整的治疗方案，另一名患者在治疗第28天发展为COVID-19；该患者无并发症恢复。
Price Action: CRVS stock is down 36.80% at $4.67 at the last check on Wednesday.
价格动态：截至周三，CRVS股票下跌36.80%，最新价格为4.67美元。
- United Microelectronics Signs Landmark Renewable Energy Deal with Fengmiao I Offshore Wind Farm, Stock Gains
- 联电与丰妙I号海上风电场签署历史性的可再生能源协议，股价上涨。
